# A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers

> **NCT00001088** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 40 (—)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** APL 400-047
- **DRUG:** Bupivacaine hydrochloride

## Key facts

- **NCT ID:** NCT00001088
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-07
- **Primary completion:** 2001-02
- **Final completion:** 2001-02
- **Target enrollment:** 40 (—)
- **Last updated:** 2008-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001088, "A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00001088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*